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“I entered the classroom with the conviction that it was crucial for me and every 
other student to be an active participant, not a passive consumer... education 
as the practice of freedom... education that connects the will to know with the 
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 ABSTRACT (English and Catalan) 
 
Abstract 
Cancer and Down Syndrome (DS), among others, are genetic diseases due to mutations 
or other alterations in cells’ DNA. PolyPurine Reverse Hoogsteen hairpins (PPRHs) have 
proved to be an efficient and specific technology for silencing or editing the genes 
involved in cancer mutations. In this research assignment, new transfecting agents in 
combination with PPRHs were tested either to improve transfection into hard-to-transfect 
cells such as lymphoma B cells using a new cationic liposome called DO-RG (dioleyl-
RG); or to improve the efficiency of this process using gold nanoparticles, which already 
have great advantages according to literature. Apart from that, DO-RG was used as a 
transfecting vehicle of specific PPRH against DYRK1A, a key protein in DS main 
cognitive deficiencies and therefore this treatment would improve DS features. DO-RG 
has previously proved to efficiently transfect neuronal origin cells. Promising results are 
obtained from the three experiment blocks; however, more replicates should be carried 
out to prove statistical significance.  
 
Resum  
El DiOleil-RG i altres derivats com a agents transfectants per incrementar 
l’eficiència de transfecció de DNA en cèl·lules difícils de transfectar.  
El càncer i la Síndrome de Down (DS), entre d’altres, són malalties genètiques a 
conseqüència de mutacions o altres alteracions en el DNA de les cèl·lules. Els 
PolyPurine Reverse Hoogsteen hairpins (PPRHs), pinces de polipurines, han resultat 
ser una tecnologia eficient pel silenciament i l’edició dels gens involucrats en les 
mutacions que provoquen el càncer. En aquest treball de recerca es proven diferents 
agents de transfecció en combinació amb els PPRHs, tant per millorar la transfecció en 
cèl·lules difícils de transfectar com són les de limfoma de cèl·lules B amb un liposoma 
catiònic anomenat DO-RG (dioleil-RG); com per millorar l’eficàcia d’aquest procés 
utilitzant nanopartícules d’or per les seves propietats positives que es descriuen a la 
literatura. A part d’això, el liposoma DO-RG s’utilitza com a vehicle de transfecció de 
PPRHs dirigits específicament en contra del gen DYRK1A, la proteïna del qual és clau 
en el desenvolupament de les deficiències cognitives característiques de la DS. Per tant, 
aquest tractament milloraria el desenvolupament de la malaltia. Prèviament, el DO-RG 
ha demostrat ser eficaç en la transfecció de cèl·lules d’origen neuronal. Els resultats 
obtinguts dels tres blocs principals d’estudi són prometedors; tot i això, s’haurien de fer 




DO-RG: Dioleyl-RG.  
 
DOTAP: Cationic liposome N-[1-(2,3-dioleoyloxy)propil]-N,N,N-trimethylammonium 
methylsulfate.  
 
DS: Down Syndrome. 
 
DYRK1A: Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A, a gene and 
a key protein in DS main cognitive deficiencies.  
 
GNP: Gold nanoparticles.   
 
HpDyrk: Different hairpins depending on the DYRK1A gene sequence they are 
directed against. All with reverse Hoogsteen bonds.  
 
HpsPr-C-F: Hairpin directed against survivin gene with reverse Hoogsteen bonds. 
 
Hps-WC-F: Hairpin directed against survivin gene with Watson and Crick bonds. 
 
PC-3: Prostate cancer cellular line.  
 
PPRH: PolyPurine Reverse-Hoogsteen hairpins. 
 
RG and LP: Name given to structures synthesized in the Organic Chemistry Department 
of the Faculty of Pharmacy of the University of Barcelona.   
 
SH-SY5Y: Neuroblastoma cellular line.  
 








 FIELDS INTEGRATION  
 
The research assignment presented below is mainly based on molecular biology, since 
it deals with the usage of PolyPurine Reverse Hoogsteen hairpins (PPRHs), DNA hairpin 
shaped molecules that, after transfection, bind the endogenous DNA and modifies the 
target gene transcription. Therefore, molecular cell processes such as DNA structure 
and transcription and translation processes are key for the understanding and 
development of the assignment. Moreover, different molecular methods such as PPRH 
design, RNA extraction or Western Blot assays, among others, were carried out.   
 
Apart from that, organic molecules were used as possible transfecting agents. A 
collaboration with the Organic Chemistry section in our Faculty was done to develop the 
cationic liposome tested (DO-RG). They also synthetized different gold nanoparticles 
that have been studied both in the laboratory experiments and in the Transmission 
Electron Microscopy (TEM) presented in this assignment. Different organic properties 
from the molecules have been discussed to improve the transfecting agents’ design.  
 
Finally, pathophysiology has been integrated to study the disordered physiological 
processes associated with cancer and Down Syndrome (DS) diseases. The 
understanding of these pathologies is basic to identify key molecules and processes on 

























I have been developing the thesis to finish my degree (TFG) in a research group of the 
Molecular Biology section in the Faculty of Pharmacy and Food Science whose line of 
work deals with cancer research using gene therapy to accomplish gene silencing and 
the editing of different genes involved in these diseases.  
 
1.1. Cancer process 
Cancer is a name given to a set of related diseases which consist of an alteration of 
different genes involved in cells functioning control, specially the growing process and 
cell division. This leads to an uncontrolled growth of these cells producing a tumour and 
the possible spread of these carcinogenic cells to other body tissues due to its invasive 
capacity.  
 
Genetic changes that contribute to the onset of cancer tend to affect three main types of 
genes: proto-oncogenes (oncogenes after their alteration), tumour suppressor genes 
and DNA repair genes. When these genes are altered, they become cancer-causing 
genes by allowing cells to proliferate uncontrollably (1).  
 
There may be one or more different mutations for cancer to appear and certain mutations 
have been found to be shared in many types of cancer. There are two main agents that 
molecularly contribute to the onset of cancer: first, the presence of an initiator agent that 
would cause a mutation in the genetic material of a cell, and second, in different 
combinations, there would be the presence of a promoter that would increase the division 
of this damaged cell. These agents that initiate or promote cancer are called carcinogens 
(2). 
 
1.2. Gene therapy 
Since cancer is a genetic origin disease, nowadays the use of nucleic acids to regulate 
and repair different cancer-causing genes is an important explored way of cancer 
therapy. Some examples of anticancer gene therapy could be the antisense 
oligonucleotides (aODNs) or the small interfering RNAs (siRNAs). Apart from these 
therapies, the PolyPurine Reverse Hoogsteen hairpins (PPRH) were first described in 
2009 (3). 
 
PPRHs are unmodified DNA molecules formed by two antiparallel mirror sequences of 
polypurines connected by 5 thymidines conforming the shape of a hairpin. The 
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intramolecular bonds established within the PPRH are inverted Hoogsteen bonds 
between the purines. On the other hand, the intermolecular bonds, established between 
the hairpin and the endogenous DNA, are created by complementary of Watson and 
Crick. Therefore, when the PPRH molecule reaches the nucleus, it is described to form 
a triplex structure with one chain of the dsDNA which displaces the second strand of 
endogenous dsDNA and blocks transcription.  
 
As it is shown in Figure 1, when PPRHs bind to the target sequence, gene expression is 
reduced by different mechanisms. On the one hand, if PPRHs bind to the template 
strand, they are called template-PPRHs and they interfere with the transcription process 
lowering mRNA and protein levels. On the other hand, if PPRHs bind to the coding 
strand, they are called coding-PPRHs, and they can block transcription factors. Likewise, 

















Figure 1. Template-PPRHs and coding-PPRHs mechanisms of action (5).  
 
All these mechanisms would end up with either a reduction in protein levels or in 
apoptosis of the cell if the PPRH blocks essential genes for cell development or function.  
 
To design PPRHs, polypyrimidine sequences must be found in the cancer-causing 
genes, more common in non-coding areas such as promoters and introns, although they 
can also be found in coding sequences. A range of up to 3 purine interruptions within 
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this polypyrimidine sequence can be accepted as it does not cause enough instability to 
avoid the PPRH binding to its target sequence.  
 
1.3. Survivin target 
One of the most commonly used PPRHs in the laboratory is that directed against survivin 
gene which decreases survivin protein levels. Survivin is an anti-apoptotic protein (does 
not allow cancer cells to die) and it is also linked to mitosis and angiogenesis processes, 
key processes for cancer development (4). This protein is over expressed in different 
tumours such as: prostate, lung, breast, colon, stomach, oesophagus, pancreas, spleen, 
uterus, ovary, non-Hodgkin’s lymphoma of large cells, leukaemia, neuroblastoma, 
melanoma and other skin cancers that are not melanomas. However, surviving levels 
are undetectable in most normal tissues differentiated with some exceptions and their 
expression is linked to less survival, resistance to chemotherapy, worse disease 
progression and higher recurrence rates. For all these reasons, survivin is considered a 
paradigm of anti-cancer target and a good marker for diagnosis and prognosis. This gene 
is the target that will be used in the first part of the experiments presented in this 
assignment. The PPRH directed against this target will be fluorescently labelled to see 
its entry into the cells and the nucleus.  
 
As the used PPRH binds to the promoter chain of gene promoter, its mechanism of action 
is through blocking transcription, therefore, it does not alter the mRNA splicing. PPRH 
sequences that target survivin gene are shown in Table 1.  
 
Gene Name  PPRH sequence  Location 














Table 1. Survivin PPRH sequences. A. Wild-type survivin hairpin with intramolecular reverse 
Hoogsteen bounds. B. Negative control survivin hairpin with intramolecular Watson and Crick 
bonds that will not allow to form a triplex with the endogenous DNA. WT – Wild type refers to the 
fact that they have up to 3 pyrimidine nucleotides facing the purines in the endogenous DNA, and 
which will not prevent the formation of the intramolecular Hoogsteen within the hairpin.  
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1.4. Transfection process and methods 
After the PPRH design, transfection must be performed. Transfection consists of 
introducing this PPRH into the cell so it can reach the nucleus and make its action. This 
transfection can be performed using different methodologies as it is explained bellow 
and each cell line has specific transfection characteristics. Generally, it has been 
described that postmitotic cells, those that have lost their ability to divide (neuronal cells 
or lymphocytes), are more difficult to transfect cells and they are commonly called hard-
to-transfect cells. These cell types are a challenge in terms of efficiency when 
introducing and expressing exogenous genetic material and much care should be taken 
while working with them. They have been described as very sensitive to different 
conditions such as physical stress or temperature alterations (6).  
 
Different mechanisms for performing nucleic acid transfection in mammalian cells have 
been described. They can be divided into two categories: those for transient transfection 
and those for stable transfection. Transient transfection is aimed at studying alterations 
in the expression of genes and proteins in the short term and, therefore, they are not 
integrated into the host cell genome. Stable transfection is aimed at generating 
integration of nucleic acids into the genome achieving a permanent expression in the 
host cell and the cells produced after its division.  
 
Transfection can be achieved using transport and release systems that can be chemical 
(liposomes, with non-liposomal lipids, polyamines or dendrimers), physical 
(electroporation or microinjection), or virus-based methods (using retroviruses, adeno-
associated virus or lentivirus).   
 
The transfection pathway used throughout the present project is transient and chemical 
through liposomes. Liposomes are synthetic analogues of the phospholipid bilayer, the 
structural basis component of the cell membrane. As shown in Figure 2, these 
transfecting agents are amphipathic, what means that they consist of hydrophobic and 
hydrophilic parts that allow the formation of spheres in water that make electrostatic 
interactions with the negative charged genetic material. It leads to the formation of lipid-
DNA aggregates that will be introduced into cells by endocytosis through the cell 
membrane (7).   
 
Some liposome features that need to be considered are cell membrane affinity for 
endocytosis and its DNA or RNA affinity for binding them but with the capability of 
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releasing the nucleic acid into the cytoplasm. These factors vary according to particle 
size, lipid formulation, amount of charge and method of liposome preparation (8). 
 
There are different advantages or disadvantages to each type of transfection that can be 
used with regard to the cells that are most difficult to be transfected. Liposome 
transfection can be said to be an easy-to-optimize technique and not too toxic to cells, 











Figure 2. Transfecting mechanism of DNA 
molecules by liposomes (9). 
 
 
1.5. DO-RG as a new transfecting agent 
In a previous research assignment for Treball Dirigit subject entitled “DO-
RG, a new transfection agent of DNA in neuronal cell”, the efficiency of 
DO-RG liposome was described.  
 
DO-RG stands for dioleyl – RG (RG as an encrypted structure) and it 
consists of a di-cationic molecule (RG) with two oleic acids attached 
(Figure 3). DO-RG achieved transfection of neuronal cells efficiently 
without intrinsic toxicity and it meant it could be a possible transfecting 
vehicle for hard-to-transfect cells.  
 
Figure 3. DO-RG molecule.  
 
1.6. Gold nanoparticles  
As described in the literature, gold nanoparticles (GNP) are useful in transfection with 






GNP have a lot of properties that make them excellent candidates for use in delivery 
applications. Some of them would be that the gold core is inert, non-toxic and 
biocompatible because it seldom reacts with other elements; the ease of fabrication 
taking into account size; the great results of the combination with different biomolecules 
such as lipids or DNA, facilitating their integration into biological systems; and finally, its 
big surface allowing great loading of therapeutic materials (10).   
 
It is also stated that the organic synthesis allows better control of the fabrication of the 
nanoparticles, however, for the biological applications, it is needed to obtain water-
soluble GNPs in order to be re-suspended in physiological fluids.  
 
Finally, the methodology which is going to be used in this project consists of a ligand 
which forms a double layer around the gold (Au) core so that the formed nanoparticles 
have positively charged heads Figure 4. Therefore, 
charged heads from the first layer stabilize the gold 
core while the charges from the second layer are 
facing outwards and making the particles soluble in 
water and ready to bind other negative charged 
compounds such as DNA (11).  
 
Figure 4. Schematic representation of GNP with a 
double layer around the gold nucleus core (water 
soluble).  
 
1.7. Down syndrome disease and molecular process 
Down Syndrome (DS) is a chromosomal condition (trisomy of chromosome 21) 
associated with intellectual impairment, a characteristic facial appearance, weak muscle 
tone (hypotonia), early onset of Alzheimer’s disease, congenital heart disease and other 
development abnormalities (12,13).  
 
The dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A (DYRK1A) gene 
is located in chromosome 21 and has been directly related with DS development. The 
expression of this gene leads to the production of a serine/threonine protein related with 
some processes in cell proliferation and survival, neuronal differentiation, synaptic 
plasticity and neurodegeneration. Therefore, an overexpression of DYRK1A would lead 
to DS brain defects which makes this gene/protein a possible therapeutic target (13,14).  
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Recent published studies have already shown benefits treating cognitive deficiencies in 
mice models by inhibiting DYRK1A kinase. Some of the used molecules have been 
obtained from natural sources or by drug screening and medical chemistry approaches. 
Apart from that, some clinical trials have already been realized in young humans. All 
conclusions highlight that DYRK1A inhibition may well be a relevant target to improve 
cognition of patients with DS (13,15).  
 
Since it is a genetic disease as well as cancer, presented before, we thought that PPRH 
technology could be applied as a treatment to DS and first tests are being presented in 
this assignment. PPRH different sequences against DYRK1A gene are shown in Table 
2. 
 
































Table 2. DYRK1A PPRH sequences located either in the promoter region or in intron number 3. 
 
In summary, PPRH have been described as efficient therapeutic technologies in genetic 








The main aim of the present work was to improve the transfection vehicles of hard-to-
transfect cells using new liposome agents such as DO-RG or GNP.  
Different strategies were followed to reach this objective: 
I. To test the efficiency of different transfecting agents as vehicles for PPRHs in 
different cellular lines.  
i. Testing the DO-RG – HpsPr-C-F complex entrance, nucleus uptake and 
cytotoxicity in a cellular line of lymphoma of B cells.  
ii. Testing the efficiency of newly synthetized gold nanoparticles in prostate 
cancer cells and in neuroblastoma cells.  
II. To apply the DO-RG properties of transfecting neuroblastoma cells as a possible 


























3. MATERIAL AND METHODS 
 
3.1. Cell culture 
Cellular lines of prostate cancer (PC-3 cells), neuroblastoma (SH-SY5Y cells) and B-cell 
lymphoma (WSU-FSCCL cells) were grown in Ham’s F12 medium supplemented with 
10% of fetal bovine serum and incubated at 37 ºC in 5% of CO2. Trypsinization of cancer 
cells was carried out to detach them using 0.05% Trypsin in PBS (phosphate buffered 
saline) 1X (154 mM NaCl, 3.88 mM NaH2PO4 and 6.1 mM NaHPO4, pH 7.4). WSU-
FSCCL cells grew on suspension.  
 
3.2. Design of PPRHs 
PPRHs were designed using the Triplex-Forming Oligonucleotide Target Sequence 
Search software. PPRHs were synthetized as non-modified desalted 
oligodeoxydenucleotides from Sygma-Aldrich and, once lyophilized, they were 
resuspended in sterile Tris-EDTA (ethylene diamine tetraacetic acid) buffer (1 mM EDTA 
and 10 mM Tris, pH 8.0) and frozen at -20 ºC until their use.   
A Watson-Crick hairpin (Hp-WC) against survivin was used as a negative control since 
it forms intramolecular Watson-Crick bonds instead of reverse Hoogsteen bonds. 
Therefore, the PPRH polypurine domain cannot bind to the polypyrimidine target 
sequence in the DNA. Specific PPRH sequences and the one for the negative control 
and their respective abbreviations are described in Table 1.  
Moreover, specific PPRH sequences against DYRK1A gene are described in Table 2. 
 
3.3. Transfection of PPRHs 
Cells were plated in 6-well dishes. Transfection mixtures were prepared including 100 
nM PPRH, 1.05-2.1 M DO-RG / 1-2 L GNP -Gold-DO-RG or Gold-ODIM- (different 
liposomes and different concentrations depending on the experiment) and completed 
with culture medium up to 200 L. The mixture was incubated for 20 min at room 
temperature and finally, the PPRH-liposome complex already aggregated was added to 
the wells obtaining a final volume of 1 mL/well. Referring to the transfecting agent 
concentration and quantity units expressed in the results point:  
• DO-RG molecular weight equate to 956 g/mol and, therefore, 1 g is equal to 
1.05 M and 2 g is equal to 2.10 M when they are incubated in a volume 
of culture medium of 1 mL.  
• Since we do not know the precise concentration of GNPs the quantity during 
the assignment will be expressed in L.  
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3.4. Structures of the transfecting agents 
DOTAP is the main liposome used during the last years in our lab. It has used to transfect 
most of the cancer cell lines with the exception of neuronal cancer cells and lymphoma 
cells. Because of this, and with a collaboration with the section of Organic Chemistry in 
our Faculty, different compounds were synthetized to allow the transfection of this hard-
to-transfect cells. These different compounds shared a common structure with two 
positive charges instead of one, as DOTAP has, and we called it RG as an encrypted 
name (since a patent is expected to be filed). Different chains were included to this RG 
structure to achieve the different molecules tested in a previous assignment I wrote for 
the Treball Dirigit subject. The best molecule achieved resulted to be Dioleyl-RG (DO-
RG) presented in Figure 5.  
Apart from that, the collaboration went on and gold nanoparticles (GNP) were 
synthetized since nanoparticles are known to facilitate the entrance of DNA to the cells. 
Throughout this assignment three gold nanoparticles are presented: Gold-DO-RG (Gold-
dioleil-RG), Gold-ODIM (Gold-Protofano-LP) and Gold-ABIM (Gold-Azobenceno-LP); 









Figure 5. Representation of (A) DOTAP structure; (B) DO-RG, ODIM and ABIM 
structures and (C) liposome attachment to Gold nanoparticle with positive charges in 
both sides of the liposome molecule to bind to both gold and DNA. 
 
DO-RG was synthetized by Rosa Griera, ODIM was synthetized by David Limón Magaña 
and all Gold nanoparticles were synthetized by the research group of Lluïsa Pérez 
García in The University of Nottingham (Akhil Jahin and Jordan Potts).  
 
DOTAP DO-RG ODIM  ABIM  GNP A) B) C) 
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3.5. Nucleus extraction 
Cells (90,000) were plated in 6-well dishes and transfected the day after. Twenty-four 
hours after transfection cells were collected in an Eppendorf®. Centrifugation was 
carried out (800 x g at 4 ºC for 5 min) and cells were resuspended gradually in 1 mL 
hypotonic buffer (HB – NaCl 15 mM, KCl 60 mM, EDTA 0.5 mM, Tris-HCl 15 mM, pH 
7.4) and let it settle 5 minutes in ice. Triton X-100 0.1% was added to break the cell 
membranes and afterwards centrifuged at 1,200 x g at 4 ºC for 10 min. Finally, cells were 
resuspended in 300 L of HB and observed in a fluorescence microscope with a 
transparent surface.  
 
3.6. Cytotoxicity assays 
Cells (10,000) were plated in 6-well dishes and transfected the day after. After 3 days 
500 g/mL of 3-(4,5-Dimethylthiazol-2-yl)-2.5-Diphenyl-tetrazolium Bromide (MTT) and 
100 M of sodium succinate were added to the culture medium in each well. After 2.5 
hours of incubation at 37 ºC to allow the reaction, the medium was removed and a 
solubilization reagent (0.57% acetic acid and 10% sodium dodecyl sulfate in dimethyl 
sulfoxide (DMSO)) was added. Absorbance was measured at 570 nm using a Modulus 
Microplate luminometer. The results were expressed as the percentage of cell survival 
taking as a reference the control well where no transfection mixture was added, only 
culture medium.  
 
3.7. RNA extraction 
Cells (30,000) were plated in 6-well dishes and transfected the day after. Total RNA was 
extracted from SH-SY5Y cells 48 h after transfection using TRIzol reagent (guanidinium 
thiocyanate brand name). The manufacturer’s specifications were followed to obtain a 
high-quality isolated RNA which was quantified by measuring its absorbance at 260 nm 
using a NanoDrop ND-1000 spectrophotometer.  
 
3.8. Reverse transcription (RT-PCR) 
Reverse transcription was performed to obtain cDNA molecules. A reaction mixture was 
prepared up to a final volume of 20 L containing 1 g of total RNA, 125 ng of random 
hexamers, 500 M of each dNTP, 2 L of 10X buffer, 20 units of RNAase inhibitor and 
200 units of Moloney murine leukemia virus reverse transcriptase (M-MLV reverse 




3.9. Real-time PCR 
The StepOnePlus Real-Time PCR System was used to perform the quantitative PCR. 
The reaction mixtures were prepared with a final volume of 20 L containing 1X SYBR 
Universal PCR Master mix, 0.25 M of reverse and forward primers, 5 L of cDNA and 
H2O mQ. The primer sequences to determine DYRK1A mRNA levels were 5’-
GTTCTTGTCAGTTGGGGCAG-3’ and 5’-TCCTGGTGGTTTGTACTCCC-3’; cyclophilin 
primers were used to normalize (or better: were used as an endogenous control) and 
their sequences were 5’-GGAGATGGCACAGGAGGAAA-3’ and 5’-
CGTAGTGCTTCAGTTTGAAGTTCTCA-3’. 
 
The reaction was performed by QuantStudio 3 Real-Time PCR System and the PCR 
cycling conditions were 10 min denaturation at 95 ºC, 40 cycles of 15 s at 95 ºC and 1 
min at 60 ºC. The mRNA quantification was calculated using the ΔΔCt method, where 
Ct is the threshold cycle that corresponds to the cycle where the amount of amplified 
mRNA reaches the threshold of fluorescence.  
 
3.10. Gel electrophoresis 
3.10.1. Agarose gel electrophoresis for binding experiments 
On the one hand a gel was prepared at 0.8% agarose in TAE buffer 1X (40 mM Tris-
acetate and 1 mM EDTA) up to a final volume of 33 mL. On the other hand, 140 ng of 
fluorescent PPRH (Hps-WC-F), different concentrations of the different liposomes and 
deionized water up to 10 L were mixed. After 20 minutes incubation at room 
temperature 2 L of loading buffer 6X were added and the 12 L samples were load into 
the gel. The gel ran at 10 V/cm and the marked PPRH with fluorescence was revealed 
in a UV lamp.  
 
3.10.2. Denaturing acrylamide gel electrophoresis (7%/4%) for protein 
Crystals and separators were assembled and sealed using 1% agarose. A 7% resolving 
solution mixture was prepared in an Erlenmeyer (7 mL acrylamide 30%, 7.5 mL resolving 
buffer Tris HCl 1.5 M, pH 8.8, 15.2 mL deionized water, a tip of spatula of persulfate, 
degasification, 300 L SDS (sodium dodecyl sulfate) 10% and 24 L TEMED 100% up 
to a final volume of 30 mL) and poured between the two crystals until polymerization. 
Next, a 4% stacking solution mixture was prepared in another Erlenmeyer (1.34 mL 
acrylamide 30%, 2.5 mL stacking buffer pH 6.8 Tris HCl 0.5 M, 6 mL deionized water, a 
tip of spatula of persulfate, degasification, 100 L SDS 10 % and 8 L TEMED 100 % 
up to a final volume of 10 mL) and poured between the two crystals until polymerization 
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including the comb to create the wells. TANK 1X buffer (Tris-Glycine SDS running buffer 
1X) was used to carry out the electrophoresis.  
 
3.11. Western blot analyses 
Total protein extracts from SH-SY5Y cells (90,000) were obtained 72 h after transfection. 
Cells were washed once with PBS 1X and collected by scrapping in 150 L of lysis buffer 
(150 mM NaCl, 1 mM EDTA, pH 8.0, 1.0% Igepal CA-630 (NP-40), 0.5 % sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM PMSF, 10 mM NAF, Protease 
inhibitor cocktail  and 50 mM Tris-HCl, pH 8.0). Centrifugation was carried out to remove 
cell remains (12,000 x g at 4ºC for 10 min).  
Whole cell extracts were resolved in 7%/4% SDS -polyacrylamide gels and transferred 
to PVDF membranes. The blocking solution was 5% Blotto. Membranes were incubated 
overnight at 4 ºC with a primary antibody against DYRK-1A (1:100 dilution; sc-100376, 
Santa Cruz Biotechnology, Heidelberg, Germany). Detection was achieved by 
secondary HRP-conjugated anti-mouse antibody (1:2500 dilution; sc-516102, Santa 
Cruz Biotechnology, Heidelberg, Germany). Chemiluminescence was detected with 
Image Quant LAS 4000 mini technology.  
 
3.12. Transmission Electron Microscopy method 
Copper grids with a carbon coating were used. An incandescent discharge treatment 
with air was applied for 30 s at 4 milliamps in a CTA 005 Glow discharge. 
5 mL of nanoparticle sample were placed on Parafilm and the copper grid was placed 
on the sample for 1 minute, followed by a drop of water for 1 minute and finally on the 
2% uranyl acetate staining agent for 1 minute, excess staining agent was removed with 
filter paper and allowed to dry at 24 ºC for at least 2 h. 
Samples were observed in a Tecnai Spirit microscope (EM) (FEI, The Netherlands) 
equipped with a LaB6 cathode. Images were acquired at 120 kV and at room 
temperature with a 1376 x 1024-pixel Megaview CCD camera. Where samples were 
entered, the acentric height, magnifications and desired focus were adjusted. 











My research project has been divided into two different assignments, the first part has 
been delivered in the “Treball Dirigit” subject and the second part is going to be my 
degree final project “Treball de Fi de Grau”, presented here. Before going on with the 
development of this point, I will sum up the results obtained on the first part of the 
research project.  
 
The research project started as a consequence that the most used liposome in our lab, 
DOTAP, did not have the capacity to transfect the known hard-to-transfect cells such as 
neuronal and lymphoma cells. Thanks to a collaboration with the section of Organic 
Chemistry in our Faculty of Pharmacy and Food Sciences, different new synthetized 
liposomes or cationic derivates were tested and one of them, DO-RG (dioleyl-RG, RG 
as an encrypted structure), resulted to be efficient in neuronal cells transfection showing 
a great apoptotic effect in combination with PPRHs against cancer-causing genes such 
as survivin and with absence of intrinsic toxicity. Some entrance and cytotoxicity 
experiments among others were carried out to support this hypothesis and it was 
concluded that DO-RG could beat the hard-to-transfect cells membrane and successfully 
transfect them.   
 
Henceforth, some of this assignment aims were on the one hand, to investigate whether 
this DO-RG liposome worked in lymphoma cells since they are also hard-to-transfect 
cells; and on the other hand, to use the DO-RG liposome as the vehicle to carry the 
DYRK1A PPRH inside neuronal cells to investigate if it could have a therapeutic effect 
for down syndrome.   
 
The results will be presented in two main parts. One part consists on the research of 
different liposome transfection methods. First, we tested the DO-RG in lymphoma cells 
since it had proved to work in other hard-to-transfect cells, such as neuroblastoma.  Next, 
gold nanoparticles in combination with the previous liposomes were tested since they 
are known to increase the transfection efficiency.  
The second part consists of an application DO-RG could have in the Down Syndrome 
treatment with specific PPRHs since this disease affects neuronal cells and DO-RG 





4.1. Transfecting agents  
4.1.1. DO-RG – HpsPr-C-F effect in WSU-FSCCL cells  
 
Since DO-RG had already been effective transfecting neuroblastoma cells there was a 
possibility that it would work in B cell lymphoma cellular line (WSU-FSCCL). Both cellular 
lines are described as hard-to-transfect cells and did not show effect using DOTAP, the 
best transfecting agent used in the lab previously.  
 
To start testing DO-RG as a transfecting agent in WSU-FSCCL cells, uptake and 
cytotoxicity experiments were carried out. In addition, nuclear extraction was performed 
to corroborate that PPRH was entering the nucleus. This experiment could be carried 
out because the PPRH used (against survivin gene, HpsPr-C-F) was marked with a 
florescent molecule so it could be observed in a fluorescence microscope.  
 
As shown below in Figure 6, different DO-RG concentration treated cells were observed 







Figure 6. Fluorescent PPRH against survivin (HpsPr-C-F) entrance in WSU-FSCCL 
cells using different DO-RG liposome concentration.  
0.5 g DO-RG 
+ 100 nM 
HpsPr-C-F 
2 g DO-RG 
+ 100 nM 
HpsPr-C-F 
1 g DO-RG 
+ 100 nM 
HpsPr-C-F 
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Fluorescent cells were observed; therefore, we could make the hypothesis that the 
complex PPRH – DO-RG liposome was achieving transfection and that the PPRH would 
be able to produce its effect in the cell nucleus.  
To go deeply, nucleus extraction experiments were performed to make sure the PPRH 
was achieving the nucleus. And, as shown in Figure 7, the results seemed to be 
satisfactory since nuclei were presented fluorescent which meant that the PPRHs were 









Figure 7. Fluorescent PPRH against survivin (HpsPr-C-F) entrance in WSU-FSCCL cell 
nucleus using 2 g of DO-RG liposome.  
 
Afterwards, cytotoxicity assays were carried out to observe and quantify the effect on the 
lymphoma cells viability. Different DO-RG concentration in combination with different 
PPRHs were tested and results are presented in Figure 8.  
 
Figure 8. Cellular viability of WSU-FSCCL cells depending on the transfection mixture 
added. [HpBCL-2 PPRH binds to a gene encoding for B cell lymphoma 2, a protein that 
regulates cell death (apoptosis). Like survivin, it is an antiapoptotic protein] (16). 
 
Although uptake experiments seemed promising, when cytotoxicity tests were carried 
out not much effect was observed. There is a chance that the effect obtained using 2 g 
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of DO-RG could be optimized. Also, it must be taken into account that this cell line is 
very sensitive and intrinsic toxicity of the liposome is easily reached. Experiments carried 
out using 3 g of DO-RG to transfect showed high toxicity.  
 
To proceed with this investigation, cell and nucleus fluorescence should be quantified in 
a flux cytometer to make sure the observed fluorescence is due to the PPRH entrance 
and not to other spread PPRH molecules which interfere in the microscope and are 
located outside of the cell or just attached to the membrane. Additionally, more 
cytotoxicity tests should be carried out to determine the most effective liposome 
concentration.   
 
4.1.2. Gold nanoparticles  
 
As explained in the introduction, gold nanoparticles (GNP) had been described in the 
literature as efficient molecules in the delivery with low inherent toxicity. Therefore, and 
once more in collaboration with the Organic Chemistry section of our Faculty it was 
decided to go a step forward and combine the DO-RG liposome, which already showed 
efficiency in transfection, with gold forming nanoparticles. Three new molecules were 
produced: Gold-DO-RG, Gold-ODIM and Gold-ABIM; and all of them were tested in the 
experimental part.  
 
To begin with, as shown in Figure 9, binding assays were performed to test whether the 
different gold nanoparticles combined with lipidic cationic molecules had the capacity to 














Figure 9. Agarose gels revealed after electrophoresis. The volume of the liposome used 
to form the complex with the PPRH is indicated in each well.  
 
Both Gold-DO-RG and Gold-ODIM presented efficacy in binding the DNA while Gold-
ABIM did not. Therefore, Gold-ABIM was no longer used. Furthermore, taking into 
account the revealed gels results it was decided that 1 L would be the appropriate 
volume to start testing these molecules in cell internalization assays.  
 
Following on, prostate cancer cells (PC-3) and neuroblastoma cells (SH-SY5Y) were 
cultured in 6-well dishes and transfected using different liposomes – GNP combined 
molecules with the presence or absence of PPRH so the liposome-PPRH effect could 
be compared with the liposome intrinsic toxicity.  
 
Before cytotoxicity assays were performed some pictures of transfection process were 
obtained with the fluorescence microscope. It can observed in Figure 10-13 that the 
liposome-PPRH complex reach the cells since the fluorescence is the result of a marker 
attached to the hairpin (PPRH) and therefore the uptake process is being successful in 
















Figure 10. Fluorescent PPRH against survivin (HpsPr-C-F) entrance in PC-3 cells using 









Figure 11. Fluorescent PPRH against survivin (HpsPr-C-F) entrance in PC-3 cells using 









Figure 12. Fluorescent PPRH against survivin (HpsPr-C-F) entrance in SH-SY5Y cells 









Figure 13. Fluorescent PPRH against survivin (HpsPr-C-F) entrance in SH-SY5Y cells 
using Gold-ODIM liposome.  
 
Once fluorescence was observed, cytotoxicity assays with different cancer cellular lines 
were carried out to determine if GNP were efficient candidates as transfecting agents. 
GNP were both tested alone and in combination with the PPRH against survivin and 





Figure 14. Cellular viability of PC-3 and SH-SY5Y cells depending on the transfection 
mixture added (Gold-DO-RG or Gold-ODIM + HpsPr-C-F). It was added 1 L of each 
liposome and 140 ng of PPRH (HpsPr-C-F).  
 
Observing Figure 14 it can be stated that Gold-DO-RG has a high effect in PC-3 cells 
and also a considerable effect in SH-SY5Y cells with no intrinsic toxicity showed in either 
of these cell lines. As far as Gold-ODIM, it was observed that it has some effect in both 
cell lines, surprisingly better in SH-SY5Y cells, known as hard-to transfect cells, but it is 
not as good as the effect of Gold-DO-RG. Apart from that, Gold-ODIM did not show much 
intrinsic cytotoxicity either.  
 
In addition to these results, Gold-DO-RG and Gold-ODIM were observed with a 
Transmission Electron Microscopy (TEM) and the photos of the different aggregates are 
presented in annex I. We can see how, in super concentrate conditions, PPRHs are 
conjugated with the liposome to form the complex. We can also observe how PPRHs 
and liposomes look like when they are alone in the sample.  
 
4.2. DO-RG applied in Down Syndrome  
 
As previously mentioned, the results of another assignment presented before clearly 
showed that the new molecule DO-RG had a great efficiency in transfecting 
neuroblastoma cells (SH-SY5Y). It was proved that the PPRH-liposome (DO-RG) 
complex could enter the cells by endocytosis and achieve the nucleus, the target location 
where the PPRH will have its effect.  
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The best transfecting agent used in the lab had been, until now, the DOTAP molecule 
that has the drawback of not lipofecting hard-to-transfect cells as neuronal or lymphoma 
cells. Therefore, the synthesis of DO-RG was a great hope for neuronal diseases as 
neuroblastoma or DS as it is going to be explained below.   
 
Since overexpression of DYRK1A protein was related with DS main features and 
cognitive deficiencies, there was the possibility that PPRHs could decrease the 
expression of this protein. Therefore, given that the DYRK1A gene is not essential for 
the cell survival the aim was to reduce the DYRK1A mRNA and protein levels and avoid 
the disease symptoms while maintaining the neurone alive.  
 
To investigate this possibility, neuroblastoma cells (SH-SY5Y) were cultured in 6-well 
dishes and treated with PPRHs directed against different polypyrimidine sequences 
found in the DYRK1A gene. PPRHs sequences are presented in Table 2.  
 
Ideally, the experimentation should had been performed using a Down Syndrome cell 
line, that we did not have available. Instead, the research work was done with 
neuroblastoma cells and the results can be a guide for later on investigation in this 
disease treatment. 
 
The experimental part started with some cytotoxicity tests, different PPRH against 
DYRK1A gene in combination with DO-RG were applied to the wells. As shown in Figure 
15, cells did not die when they were treated and the lowest cell viability observed was 
more than 80%, therefore, RNA extraction experiments were interesting to carry out. 
Figure 15. Cellular viability of SH-SY5Y cells depending on the transfection mixture 
added. 
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Following on, RNA extraction and specific quantification of DYRK1A mRNA levels were 
performed to observe the mRNA levels variation. Results are shown below in Figure 16.  
Figure 16. mRNA levels depending on the effect the PPRH against DYRK gene has 
achieved.  
 
DYRK1A mRNA levels were decreased between 30 and 60 % depending on the PPRH 
used. The lowest levels were achieved with HpDyrk-Pr-T and HpDyrk-13-C-L. With these 
results and according to the papers referred to in the introduction it could be stated that 
PPRH gene therapy could be a possible treatment for DS. However, more experiments 
and optimization of the therapy should be investigated to support this hypothesis. A 
following step could be the quantification of protein levels to compare it with mRNA levels 
and see if there is a concordance between them.  
 
According to this planning, a first western blot was made but the protein extraction was 
not satisfactory, and therefore, the results are not going to be presented. Despite this, 
the new primary antibody against DYRK1A protein was proved to work and showed good 
signal at 90 kDa level (Figure 17), which is in accordance with the molecular weight of 
the protein. Therefore, new experiments should be done to make progress in the project.  
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Figure 17. Protein levels detected in a first western blot carried out using an antibody 
against DYRK1A protein. Left columns are referred to different combinations of control 
and treated SH-SY5Y cells protein while the right column is the marker to know how the 
electrophoresis is going and where your protein is according to its size.  
 
Results are not decisive since protein extraction did not perfectly work but we decided 
to go on with the western blot to test the antibody since it was the first time it was being 









The research experiments I have been conducting in the laboratory have a broad 
spectrum, with different long-term aims as it is exposed previously. First steps are being 
performed to make an approach of how these aims look like and it concludes opening 
doors for future projects.  
 
As presented in the aims section, the development of the research consisted of two main 
parts. In the first one, related to transfecting agents, DO-RG capability was tested in 
other hard-to-transfect cells while new gold nanoparticles were tested as an innovation 
in the laboratory. The second one dealt with the application of DO-RG-PPRH as a 
possible Down Syndrome therapy.  
 
First of all, lymphoma B cells were transfected using DO-RG, a new cationic liposome 
that had proved to efficiently work in neuronal cells, both hard-to-transfect cells. 
Transfection seems to have succeeded as fluorescent cells and nucleus were observed. 
However, cytotoxicity tests showed a maximum effect of 40%. More cytotoxicity tests 
should be carried out and try to optimize the best dose observed. Achieving transfection 
in hard-to-transfect cells is a really ambitious aim for scientist community and it would 
mean an interesting discovery.  
 
Apart from going on testing DO-RG, new forecasts related to gold nanoparticles seemed 
that could work. Some meetings and analyses of the aim were done together with the 
scientists from the Organic Chemistry section of the Faculty, and as a result, three new 
cationic liposomes combined with gold were synthetized. As it was described in the 
literature, they could increase the efficacy in transfecting DNA or other molecules. 
 
These three molecules started to be tested in our laboratory, in the Molecular Biology 
section, and some studies such as the PPRH-GNP entrance succeeded as we could see 
fluorescent cells in the microscope due to the fluorescence mark in the PPRH. 
Cytotoxicity tests showed effect as well, the combination of GNP with PPRH reduced cell 
viability levels being Gold-DO-RG the most efficient transfecting agent out of the three.  
 
The results achieved seem to be very positive although more tests should be performed 
to make sure the level of efficiency when combined with the PPRH, excluding the intrinsic 
toxicity of GNP. Furthermore, these achievements should be compared to the effect 
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exerted by DO-RG-PPRH complexes to determine if GNP really increase the transfecting 
capacity of these liposomes.  
 
The last aim consisted of applying the DO-RG capacity of transfecting neuronal cells to 
study if it could be a possible treatment for Down Syndrome patients. Since 
overexpression of DYRK1A protein was described in the literature as a main feature for 
cognitive disorders, we aimed at using PPRH to decrease the expression of these gene 
and therefore decrease the disease manifestations. Different PPRH against DYRK1A 
gene were designed and tested in neuroblastoma cells, since we could not obtain a DS 
cell line. Positive results were obtained from cytotoxicity tests since cells did not die with 
the DO-RG-PPRH treatment while RNA levels were observed to decrease in RNA 
extraction experiments. In a near future, further experiments as quantification of protein 
levels should be carried out to show more evidence and in this assignment the antibody 
which binds to DYRK1A protein already is proved to work.  
 
As a global analysis, all the three points of the study have positive results and seem a 
possible field to explore. However, although different experiment replicas have been 
carried out more tests should be performed to validate them with statistical significance.  
 
After drug discovery processes, further steps such as preclinical trials in animals should 
be carried out. Finally, clinical trials including all genders and ethnicities should be 



















In this study different experiments have been carried out to contribute to cancer and 
Down Syndrome gene therapy research in mammalian cells. Different transfecting 
strategies have been developed and it can be concluded that:  
- DO-RG – HpsPr-C-F complex seems to achieve entrance and nucleus release 
in hard-to-transfect cells such as lymphoma B cells and neurons. The effect can 
be observed already with 2 µg of the liposome in cytotoxicity assays without 
presenting intrinsic toxicity.  
- Two out of the three new Gold nanoparticles synthesised and tested proved to 
be efficient as transfecting agents (Gold-DO-RG more than Gold-ODIM) without 
intrinsic toxicity in combination with HpsPr-C-F. 
As far as the application of DO-RG transfecting properties in neuronal cells in Down 
Syndrome:  
- According to the experiments performed in neuroblastoma cells, DO-RG together 
with a PPRH against DYRK1A gene seem to reduce mRNA levels without 
cytotoxic effects in cells. If the protein levels were also reduced, this approach 
could very well be highly positive for DS therapy, as DYRK1A is responsible of a 
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ANNEX I (TEM images) 
 
Transmission Electronic Microscopy (TEM) images obtained in the Parc Científic de 
Barcelona in collaboration with David Limón from the Organic Chemistry section of the 
Faculty.  
The photos show different samples including isolated PPRH and the different GNP alone 
and in combination with the PPRH. Furthermore, a more distant photo is presented on 




PPRHs were observed without nanoparticles as a control. The only kind of material that 
can be observed in both samples is curled fibres, which can be stained either negatively 
(dark surroundings, clear organic material) or positively (dark material). 
 





It is possible that the observed fibres are composed of ODIM, where ODIM self-
assembles in presence of water to form them. Nanoparticles (dark points) vary in shape, 
observing circular, oval, triangular and polyhedral forms, and vary in size. Moreover, the 
organic coating thickness is in accordance with a bilayer model (light coating).  
 
Sample composition: GNP.ODIM 1.3 nM in miliQ water.  
 
GNP.ODIM – PPRH 
 
These observations suggest that the fibres in GNP.ODIM are composed of ODIM, and 
when the sample is in contact with the PPRH, both ODIM fibres and the nanoparticles 
(covered with ODIM as well) strongly interact with the PPRH, adopting the arrangement 




Sample composition: GNP.ODIM 1.3 nM, PPRH 5 µM, Tris·HCl-EDTA (TE) 500 µM in 








GNP.DOPI shows nanoparticles arranged in clusters (1 to more than 20 nanoparticles 
per cluster). Clusters of nanoparticles are formed by spheres of DO-RG containing the 
gold nanoparticles. These clusters of nanoparticles are not interacting with each other, 
as they are completely dispersed along the sample. 
 
 
Sample composition: GNP.DO-RG 359 nM in miliQ water.  
 
GNP.DO-RG – PPRH 
 
Nanoparticles are grouped in clusters recovered of negatively stained material, which is 




Sample composition: GNP.DO-RG 359 nM, PPRH 5 µM, Tris·HCl-EDTA (TE) 500 µM 
in miliQ water. 
